Disclosure
We are short shares of Proteostasis Therapeutics, Inc. Please click here to read full disclosures.
Kerrisdale Capital will host a conference call on Tuesday, March 20 at 10:30am ET to discuss the Proteostasis Therapeutics report.
To participate in the conference call, dial 866-834-3313 (US) or 409-981-0700 (international) and reference the Kerrisdale Capital call.
We are short shares of Proteostasis Therapeutics, a clinical-stage biopharmaceutical company whose lead drug, PTI-428, aims to treat the genetic disorder cystic fibrosis. Proteostasis claims that the drug works in a unique way, by somehow increasing the levels of messenger RNA and protein corresponding to the so-called CFTR gene that is dysfunctionally mutated in people with the disease and that gives rise to its ultimately fatal symptoms.
In December, Proteostasis released results from a small Phase 2 proof-of-concept clinical trial, supposedly showing that PTI-428 meaningfully improved lung function relative to placebo. On the back of these results, the company announced last week that the FDA had granted it “breakthrough therapy” designation, a relatively minor development that nonetheless sparked a ~100% spike in the company’s stock price. Over the following five trading days, Proteostasis’s entire share count turned over more than twice, strongly suggesting an influx of new and potentially uninformed investors. The company quickly capitalized on this surge by announcing a nine-million share public offering last night – apparently as eager to sell shares at recent prices as we are.
Contrary to Proteostasis’s hype, we believe that its Phase 2 results are far less meaningful than they appear. The main reason that PTI-428 looks good is not that patients who received it performed unusually well but that the four placebo patients to whom they were compared performed unusually poorly. Judged by a more reasonable benchmark, PTI-428 seems to do little – echoing an earlier, more obviously disappointing Phase 1 trial in which the drug yielded no statistically significant improvement in lung function.
While Proteostasis touts changes in CFTR mRNA and protein levels as key signals that PTI-428 is working as intended, closer inspection reveals a wide range of data-quality problems and red flags, such as the absence of consistent dose-response relationships. Given the scarcity of CFTR mRNA and protein even in the airway epithelium, we doubt that Proteostasis can reliably measure its favored biomarkers, calling into question its fundamental understanding of its own drug. Indeed, we find it difficult to trust the company’s data, given its tendency to gloss over potentially negative facts. For instance, while a group of partially independent researchers have recently found that, in one in vitro model, PTI-428 failed to increase CFTR protein levels or functionality to a statistically significant degree, either on its own or when added to standard-of-care drugs, Proteostasis management has ignored the unpleasant results, even though three Proteostasis employees were co-authors on the paper.
With an ineffective lead drug and unpromising pipeline, Proteostasis has little value; we estimate 70-90% downside, based on cash per share. There is little value in PTI’s misleadingly spun data, bizarrely noisy biomarkers, and selectively disclosed results. Alas, it’s far easier to inflate weak data than it is to inflate ailing lungs.
Read our full report here.




Add New Comment